A Retrospective, Multi-center Chart Review to Confirm Safety and Effectiveness of Belotero® Revive for Facial Skin Revitalization

A Retrospective, Multi-center Chart Review to Confirm Safety and Effectiveness of Belotero® Revive for Facial Skin Revitalization - BELOVE 3.0

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035911

Enrollment

200

Registered

2025-05-30

Start date

2025-07-22

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial skin revitalization

Interventions

Group 1: In the context of this post-market observational follow-up study, charts of participants who were treated with Belotero Revive for facial skin revitalization at sites in the European Union (E

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male and female participants aged at least 18 years at the time of treatment, 2. Written informed consent obtained, 3. Participants treated with Belotero Revive for facial skin revitalization in the cheeks area from April 2019 (commercialization date) to present time.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Aim of the study is to collect additional data on safety and effectiveness of Belotero Revive for facial skin revitalization in males and females 18 years old and older. • Ease of injection (easy, difficult), • Skin hydration (satisfying, not satisfying), • Skin elasticity (satisfying, not satisfying), • Skin firmness (satisfying, not satisfying), • Skin quality in terms of smoothening of superficial fine lines / reduction in skin roughness (satisfying, not satisfying), • Injection site reactions (erythema, swelling, pain, bruising, hematoma, other), • Adverse Event (AEs) (causal relationship, seriousness, time of occurrence, severity and duration).	—

Measure

Time frame

Aim of the study is to collect additional data on safety and effectiveness of Belotero Revive for facial skin revitalization in males and females 18 years old and older. • Ease of injection (easy, difficult), • Skin hydration (satisfying, not satisfying), • Skin elasticity (satisfying, not satisfying), • Skin firmness (satisfying, not satisfying), • Skin quality in terms of smoothening of superficial fine lines / reduction in skin roughness (satisfying, not satisfying), • Injection site reactions (erythema, swelling, pain, bruising, hematoma, other), • Adverse Event (AEs) (causal relationship, seriousness, time of occurrence, severity and duration).

—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026